- Research works
- 114 ▲ 218% vs 2013–17
- Citations
- 4.2k 36.8 per fractional work
- Top-10% rate
- 9.3% record average 16.5%
- Open access
- 47% world 28%
Not ranked overall: Biognosys (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Chemistry, 9.6×. Every wedge is a field page.
- Chemistry 9.6×
- Immunology and Microbiology 8.9×
- Biochemistry, Genetics and Molecular Biology 5.2×
- Medicine 2.0×
- Neuroscience 1.2×
- Physics and Astronomy 0.9×
- Decision Sciences 0.3×
- Pharmacology, Toxicology and Pharmaceutics 0.2×
- Engineering 0.2×
- Computer Science 0.2×
- Environmental Science 0.1×
- Agricultural and Biological Sciences 0.1×
Who are the top researchers at Biognosys (Switzerland)?
Ranked on the composite score, Lukas Reiter lead among researchers whose main affiliation is Biognosys (Switzerland).
- 1 Lukas Reiter Switzerland · #600,902 worldwide 86 citations · 19 works
Which keywords describe research at Biognosys (Switzerland)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Mass Spectrometry, Proteomics, Tumor Microenvironment, Quantitative Analysis, Tandem Mass Spectrometry, Phosphoproteomics, Protein Identification and Cancer Immunotherapy.
- Pulmonary Sclerosing Hemangioma
- Synthetic Biology
- Mutational Signatures
- Ferroptosis
- Cancer Genomics
- Genomic Instability
- Gene Expression
- Tumor Antigen
- PD-1 and PD-L1
- Immune Checkpoint Blockade
- Imaging
- Immunity
- Fc Receptors
- Therapeutic Antibodies
- Antigen Presentation
- Cancer
- Cancer Immunotherapy
- Phosphoproteomics
- Quantitative Analysis
- Proteomics
- Mass Spectrometry
- Tumor Microenvironment
- Tandem Mass Spectrometry
- Protein Identification
- Glycosylation
- Immunotherapy
- Monoclonal Antibodies
- Antibody Engineering
- Dendritic Cells
- Innate Immunity
- Electrospray
- Ionization
- Targeted Therapy
- Vaccine Adjuvants
- Cell Death
- Tumor Regression
- Cancer Therapy
- Lipid Peroxidation
- Tumor Targeting
- Pulmonary Alveolar Microlithiasis
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Mass Spectrometry7▲ 90×3 topics
- Proteomics7▲ 219×2 topics
- Tumor Microenvironment6▲ 25×6 topics
- Quantitative Analysis5▲ 51×2 topics
- Tandem Mass Spectrometry5▲ 185×2 topics
- Phosphoproteomics5▲ 561×1 topic
- Protein Identification5▲ 561×1 topic
- Cancer Immunotherapy4▲ 45×3 topics
- Glycosylation4▲ 61×2 topics
- Cancer3▲ 4.8×12 topics
- Immunotherapy3▲ 8.9×8 topics
- Antigen Presentation3▲ 68×2 topics
- Monoclonal Antibodies3▲ 67×2 topics
- Therapeutic Antibodies3▲ 86×2 topics
- Antibody Engineering3▲ 106×1 topic
- Fc Receptors3▲ 106×1 topic
- Dendritic Cells3▲ 57×2 topics
- Immunity3▲ 13×5 topics
- Innate Immunity3▲ 16×3 topics
- Imaging2▲ 19×2 topics
- Electrospray2▲ 128×1 topic
- Immune Checkpoint Blockade2▲ 38×1 topic
- Ionization2▲ 128×1 topic
- PD-1 and PD-L12▲ 38×1 topic
- Targeted Therapy2▲ 19×3 topics
- Tumor Antigen2▲ 68×1 topic
- Vaccine Adjuvants2▲ 68×1 topic
- Gene Expression2▲ 6.6×3 topics
- Cell Death2▲ 14×3 topics
- Genomic Instability2▲ 30×3 topics
- Tumor Regression2▲ 30×2 topics
- Cancer Genomics2▲ 43×1 topic
- Cancer Therapy2▲ 5.3×5 topics
- Ferroptosis2▲ 39×1 topic
- Lipid Peroxidation2▲ 29×1 topic
- Mutational Signatures2▲ 43×1 topic
- Tumor Targeting2▲ 16×2 topics
- Synthetic Biology1▲ 43×2 topics
- Pulmonary Alveolar Microlithiasis1▲ 97×1 topic
- Pulmonary Sclerosing Hemangioma1▲ 97×1 topic
Which research topics does Biognosys (Switzerland) publish most on?
By volume in 2022–2025: Advanced Proteomics Techniques and Applications, Monoclonal and Polyclonal Antibodies Research, Cancer Immunotherapy and Biomarkers and Mass Spectrometry Techniques and Applications.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced Proteomics Techniques and Applications Spectroscopy 5 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 4 Mass Spectrometry Techniques and Applications Spectroscopy 2 works
- 5 Immunotherapy and Immune Responses Immunology 2 works
- 6 Cancer Genomics and Diagnostics Cancer Research 2 works
- 7 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 2 works
- 8 Advanced Biosensing Techniques and Applications Molecular Biology 1 works
- 9 Medical Imaging and Pathology Studies Pulmonary and Respiratory Medicine 1 works
- 10 vaccines and immunoinformatics approaches Molecular Biology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Biognosys (Switzerland)'s research output changed?
Output in 2018–2022 was 218% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Schlieren
- Spital Limmattal
- Cell Medica (Switzerland)
- Molecular Partners (Switzerland)
- Kuros Biosciences (Switzerland)
- Exalos (Switzerland)
- Neurotune (Switzerland)
- Foundation for People with Rare Diseases
- Arcadis (Switzerland)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.